Hartley Medical Center Pharmacy Recalls Hydromorphone and Baclofen Syringes
Hartley Medical Center Pharmacy is recalling specific hydromorphone and baclofen syringes due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls involving significant risks like sterility issues (which can lead to infection) are typically rated as Severe (4), especially when no specific Class I designation is present but the hazard is significant.
Plain-English summary
Hartley Medical Center Pharmacy, Incorporated is recalling Hydromorphone 12 mg/ml/Baclofen 450 mcg/ml, vol. 20 ml, syringes. The recall is being conducted because of a lack of assurance of sterility for the product.
The affected product is a prescription-only syringe manufactured by Hartley Medical Center Pharmacy, Incorporated, located in Long Beach, CA. The specific lot identified for recall has a best-use date of 5/3/2016. The product was distributed nationwide, with no foreign distribution reported.
Consumers and healthcare providers should stop using the affected syringes and contact their pharmacist or the recalling firm for further instructions on how to return or dispose of the product.
The recalled product
- Product
- Hydromorphone 12 mg/ml/Baclofen 450 mcg/ml, vol. 20 ml, syringe, Rx only, Hartley Med Ctr Pharmacy, Long Beach, CA
- Manufacturer
- Hartley Medical Center Pharmacy, Incorporated
- Category
- Drug — Injectable
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- BUD: 5/3/2016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 30 recalled by Hartley Medical Center Pharmacy, Incorporated under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 30 products in this recall →Related recalls
Same manufacturer · Hartley Medical Center Pharmacy, Incorporated
See all →- SevereHartley Medical Center Pharmacy Recalls Sufentanil Citrate Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-03-16
- SevereHartley Medical Center Pharmacy Recalls Baclofen Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-03-16
- SevereHartley Medical Center Pharmacy Recalls Baclofen Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-03-16
- SevereMorphine Sulfate Syringes Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2016-03-16
- SevereHartley Medical Center Pharmacy Recalls Morphine and Bupivacaine Syringes
FDA (Drugs) · 2016-03-16
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Hydromorphone Syringes Due to Sterility Concerns
FDA (Drugs) · 2017-11-01
- SevereCantrell Drug Recalls Hydromorphone Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-12-21
- HighFDA Recalls HYDROmorphone Syringes for Sterility Assurance Issue
FDA (Drugs) · 2023-10-11
- HighHYDROmorphone HCl 6 mg Injectable Syringes Recalled Due to Sterility Assurance Issues
FDA (Drugs) · 2024-04-03
- HighHydromorphone Syringe Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighHydromorphone Injection Syringes Recalled for Sterility Validation Deficiency
FDA (Drugs) · 2023-08-09